Exclusivity For Biologics Should Potentially Be Longer Than For Small Molecule Drugs – BIO Exec
This article was originally published in The Pink Sheet Daily
Executive Summary
In debate over follow-on biologics pathway, BIO and GPhA agree on little except the need to lay out intellectual property ground rules.
You may also be interested in...
BIO Establishes Principles For Follow-on Biologics To Guide Lawmakers
In letters sent to legislators, BIO asks Congress to adopt the principles, emphasizing patient health and biotech innovation.
BIO Establishes Principles For Follow-on Biologics To Guide Lawmakers
In letters sent to legislators, BIO asks Congress to adopt the principles, emphasizing patient health and biotech innovation.
Budget Office Savings Estimates For Follow-On Biologics May Be Modest – McClellan
Follow-on biologics savings estimates by the Congressional Budget Office could “take some wind out of the sails” to develop legislation, the former FDA commissioner says.